Dynavox Group stock
DYVOX.STSTODynavox Group AB (publ), HealthcareISIN SE0017105620
67Score 67 out of 100, Neutral
Price and trend
45 / 100
Price history
−21% in one yearThe chart shows daily closes over 5 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 4.8% below it.
Since December 2025 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 58).
The price is 30% below its 52-week high. Largest decline in 5 years: 56% (July 2025 to June 2026).
Chart figures for advanced users
- SMA 50$7.58
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$7.77
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)58
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$5.83
- The lowest closing price of the last twelve months.
- Resistance$10.51
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Dynavox Group AB (publ) belongs to the Medical (Instruments & Supplies) industry (Sweden) and, with a market value of $784.35M, is number 41 of 44 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $247.38M (up 25.1% year on year) and earnings of $16.61M (up 13.6%).
- For fiscal 2026, analysts expect on average revenue of $274.57M (up 11%) and adjusted earnings per share of $0.30 (up 58%).
Show more
- MEQIRI Score 67 out of 100 (Neutral): rank 178 of 702 in Healthcare, median 53.
- The P/E is 28.5 (Medical (Instruments & Supplies) median 34.6, own median of recent years 46.3).
- Our model puts fair value at $11.85, with the price 38% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 22.5% a year since 2020, Medical (Instruments & Supplies) median 9.5%.Growth 83
- Below fair valuePrice 38% below the fair value of $11.85.Valuation 72
- Analysts expect strong earnings growthUp 25.9% a year through 2028 (estimates from 4 analysts).Growth 83
Weaknesses
- High debtDebt 1.33 times equity (latest quarter), Medical (Instruments & Supplies) median 0.45.Stability 53
- Volatile share priceVolatility 48% a year over the last 12 months.Stability 53
Its standout strengths are growth and profitability, while technical analysis and momentum hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 66 to 67.
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high growth grade (crashed more often in the backtest)
- high price swings
What lowers it
- solid fundamentals
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $8.46 and expensive above $19.75 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $14.73 (cash-flow model) and $8.97 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 7.2%. At 8.2% the fair value would be $10.49, at 6.2% it would be $13.90.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (34.6).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 10.3% on the twelve months before. Revenue has grown strongly since 2019, at around 18% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 68%, operating 10%, net 7%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 4 Feb 2027in 83 days
- Last reported
- 21 Oct 2026EPS reported $0.08 (expected $0.08)above expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 6.2% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- $0.30+1.1%
- Revenue
- $274.57M−1.6%
- Earnings per share
- $0.39−6.2%
- Revenue
- $324.19M−2.7%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +10.0%No guidance change: the goal remains a full year EBIT margin of at least 15%, with gross margin facing a headwind of slightly below one percentage point over the next 12 months.
“The outlook is that we think that slightly below one percentage point will have an impact on the gross margin if we look at the coming 12 months perspective.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 22 Jul 2026 (fiscal Q2 2026), read by AI.
What happened at Dynavox Group
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 67
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Instruments & Supplies)
The next larger and next smaller companies by market value
- LeMaitre VascularLMAT $1.78B70
- Kestra Medical TechnologiesKMTS $1.7B43
- STAAR SurgicalSTAA $1.34B44
- GerresheimerGXI.DE $1.21B48
- Safilo GroupSFL.MI $1.01B61
- AngioDynamicsANGO $504.23M39
- EmbectaEMBC $364.32M63
- COLTENE HoldingCLTN.SW $347.49M61
ETFs that hold Dynavox Group
Held by 10 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Healthcare Innovation UCITS ETF2B78 | 0.07% | 0.40% | €1.5B |
| iShares Ageing Population UCITS ETF2B77 | 0.06% | 0.40% | €813.42M |
| Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF DistX026 | 0.05% | 0.23% | €321.86M |
Show 5 more
| Xtrackers MSCI Europe Small Cap UCITS ETF 1CXXSC | 0.05% | 0.30% | €3.45B |
| Avantis Global Small Cap Value UCITS ETFAVWS | 0.03% | 0.39% | €1.49B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.01% | 0.10% | €395.74M |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.01% | 0.35% | €8.27B |
| State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR AccZPRX | 0.01% | 0.30% | €813.64M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = SEK 9.9729)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 26 Sep 2025)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.